The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,488
Sort by:
Investigation Report on China Epoetin Alfa Market, 2009-2018
US$ 1,800.00
... by kidney and liver that stimulates erythropoiesis. Indications of EOP approved in China are renal anemia, anemia after chemotherapy and surgery perioperative ... space for EPO used in anemia after chemotherapy in China. Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by ...
March 2014
40 pages
Investigation Report on China Imatinib Market, 2009-2018
US$ 1,800.00
... approved to China in 2002 to treat CML and GIST. Its market size keeps increasing after its launch. According to CRI's investigation on sample ... Hospital Market Incidence of CML in China Manufacturing Schedule of Imatinib Generic Drug Prospect of China Imatinib Market The following enterprises and people ...
March 2014
40 pages
Investigation Report on China Aripiprazole Market, 2009-2018
US$ 1,800.00
... the end of 2013 there have been over 10 million schizophrenia patients in China, and the number is still increasing year after year. Schizophrenia ... in Different Dosage Forms in China Hospital Market Prospect of China Aripiprazole Market The following enterprises and people are recommended to purchase this ...
March 2014
40 pages
Investigation Report on China Enoxaparin Sodium Market, 2009-2018
US$ 1,800.00
... , and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have ... Market Production Status of Enoxaparin Sodium Generic Drug in China Major Enoxaparin Sodium Manufacturers in China Prospect of China Enoxaparin Sodium Market The ...
February 2014
40 pages
Investigation Report on China Pemetrexed Market, 2009-2018
US$ 1,800.00
... value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only ... China Hospital Market Incidence of Cancer in China Manufacturing Schedule of Pemetrexed generic drug Prospect of China Pemetrexed Market The following enterprises and people ...
February 2014
40 pages
Vitamin Price in China
US$ 2,979.00
... benchmarking research studying the cost structure of Chinese vitamin C and the competitiveness of major Chinese players. ... set up the model and verify afterwards. The breakeven price of Chinese products is concluded. The aim of ... as how to penetrate the ever-increasing China market and how to catch the maximum ...
February 2014
6 pages
Investigation Report on China Bevacizumab Market, 2009-2018
US$ 1,800.00
... remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the ... Dosage Forms in Hospital Market in China Incidence of Cancer in China Manufacturing Schedule of Bevacizumab generic drug Prospect of China Bevacizumab Market The author ...
February 2014
40 pages
Investigation Report on China Duloxetine Market, 2009-2018
US$ 1,800.00
... increasing, which nearly reached USD 5 billion in 2012. The success of duloxetine sales also comes from its persistent exploration and study ... in Different Dosage Forms in China Hospital Market Prospect of China Duloxetine Market The author recommends the report to the following: Antidepressant APIs ...
February 2014
40 pages
Investigation Report on China Valsartan Market, 2009-2018
US$ 1,800.00
... can acquire the following information: Market Share of Major Valsartan Manufacturers in Sampling Hospitals in China Sales price of valsartan in hospital market in China Major valsartan enterprises in China Market share of valsartan by dosage form in hospital market in China Prospect of China valsartan ...
February 2014
40 pages
Europe Orphan Drug Market Outlook 2018
US$ 1,200.00
... orphan drugs. “Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market: Europe Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework Europe ...
February 2014
134 pages
US Orphan Drug Market Outlook 2018
US$ 1,200.00
... . “US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market: US Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework US Orphan Drug ...
February 2014
160 pages
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
US$ 2,873.00
... Pipeline Analysis The report entitled Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more ... arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs. ...
January 2014
347 pages
World Drugs of Abuse Testing Market: Emerging Tests, Technology Assessment, Instrumentation Review, Market Shares, Sales Forecasts, and Strategic Profiles, of Key Players
US$ 6,800.00
... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , controls, calibrators and others. “2014 Analysis of the Global Drugs of Abuse Testing Market” is a unique study designed to help current suppliers and ...
January 2014
318 pages
Europe Alzheimer's Disease Drug Pipeline Analysis
US$ 1,500.00
... / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase: Research: 19 Preclinical: 49 Clinical: 1 Phase-I: 25 Phase-I/II: 2 Phase-II: 26 Phase-II/III: 2 Phase-III: 5 Preregistration: 2 Marketed: 10 Unknown: 1
January 2014
265 pages
Europe Parkinson’s Disease Drug Pipeline Analysis
US$ 1,000.00
... for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Parkinson’s Disease Drug Pipeline by Clinical Phase: Research: 12 Clinical: 26 Phase-I: 14 Phase-I/II: 2 Phase-II: 6 Phase-II/III: 1 Phase-III: 3 Preregistration: 1 Marketed: 18
January 2014
199 pages
US Skin Cancer Drug Pipeline Analysis
US$ 1,200.00
... Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Number of Skin Cancer Drug in Pipeline by Clinical Phase: Research: 3 Preclinical: 29 Clinical: 5 Phase 0: 1 Phase-I: 29 Phase-I/II: 18 Phase-II: 41 Phase-III: 13 Registered: 4 Marketed: 18 Unknown: 1
January 2014
310 pages
Japan Cancer Drug Pipeline Analysis
US$ 1,500.00
... for the pharma companies in their every-day decision making. “Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process. Following parameters for ...
January 2014
557 pages
Europe Lung Cancer Drug Pipeline Analysis
US$ 1,200.00
... identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process. Following parameters for ... drug profile in development phase are covered in “Europe Lung Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...
January 2014
340 pages
Europe Orphan Drug Pipeline Analysis 2014
US$ 2,400.00
... in the Europe orphan designated drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Orphan Drug Pipeline Analysis 2014” research report: Drug Profile Overview Active Indication ...
January 2014
1430 pages
Personalizing Cancer Drugs Trends: Market Research Report
US$ 1,450.00
... pace of growth is not being reported in the area of development of drugs and therapies for treating cancers. The report also predicts that the ... analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with ...
December 2013
28 pages
Global and China Insulin Industry Report, 2013-2017
US$ 1,900.00
... Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical ... also received clinical approval issued by SFDA in September 2013. Global and China Insulin Industry Report, 2013-2017 mainly covers the ...
December 2013
80 pages
2014 Opportunities in the UK Therapeutic Drug Monitoring (TDM) Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
247 pages
2014 Opportunities in the US Therapeutic Drug Monitoring (TDM) Market
US$ 2,800.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
249 pages
2014 Opportunities in the Spanish Drugs of Abuse Testing Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
260 pages
2014 Opportunities in the UK Drugs of Abuse Testing Market
US$ 1,960.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
260 pages
2014 Opportunities in the US Drugs of Abuse Testing Market
US$ 2,800.00
... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...
December 2013
262 pages
2014 Opportunities in the European Drugs of Abuse Testing Market
US$ 5,200.00
This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
December 2013
300 pages
Research Report on China Antidiabetic Drug Market, 2014-2018
US$ 2,400.00
... and cure to diabetes become more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the ... . The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%. For global pharmaceutical ...
December 2013
60 pages
Market Access for Orphan Drugs: assessing the global landscape
US$ 595.00
... high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies. In Market Access for Orphan Drugs: Assessing the Global Landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the ...
November 2013
100 pages
The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023
US$ 3,000.00
... reach $143.7bn by 2023. GMR Data’s latest report 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ explains just how ... Within GMR Data’s 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ we analyse the key cancer drugs and treatments in the market currently and ...
November 2013
243 pages
2014 Nucleic Acid Testing Market: Strategic Assessments of Leading Strategic Suppliers
US$ 2,800.00
This 549-page report presents an overview of the clinical significance and market needs for major current and emerging NAT assays, as well as ... assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, ...
November 2013
549 pages
Research Report on China Osteoporosis Drug Market, 2013-2017
US$ 1,800.00
... vitamin D and analogues, and calcitonins always took up above 98% shares of China osteoporosis drug market. The market share of bisphosphonates increased at the ... global pharmaceutical enterprises, they will find huge market opportunities in China. Through this report, the readers can acquire the following ...
November 2013
30 pages
2014 Analysis of the Global Drugs of Abuse Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan
US$ 6,800.00
... (test volumes, sales forecasts, supplier shares) $5,500. This new 318-page report from Venture Planning Group contains 68 tables and provides analysis of the global drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic ...
November 2013
318 pages
2014 Analysis of the UK Drugs of Abuse Testing Market: Hospitals and Commercial Labs
US$ 1,960.00
This new 260-page report from Venture Planning Group provides a comprehensive analysis of the UK drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
November 2013
260 pages
2014 Analysis of the European Drugs of Abuse Testing Market: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers
US$ 5,200.00
This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...
November 2013
300 pages
2014 Analysis of the Global Therapeutic Drug Monitoring (TDM) Market: US, Europe (France, Germany, Italy, Spain, UK), Japan
US$ 6,800.00
... volumes, sales forecasts, supplier shares) $5,500. This new 313-page report from Venture Planning Group contains 83 tables and provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and ...
November 2013
313 pages
